CANCER TREATMENT HOLDINGS INC
NT 10-K, 2000-08-29
HOME HEALTH CARE SERVICES
Previous: IDS UTILITIES INCOME FUND INC, NSAR-B, EX-99, 2000-08-29
Next: DATALINK NET INC, 424B3, 2000-08-29



<PAGE>

                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 12b-25
                                                  Commission File Number 1-11062


                           NOTIFICATION OF LATE FILING

(Check One): [X] Form 10-K [ ] Form 11-K [ ] Form 20-F [X] Form 10-Q
             [ ] Form N-SAR

For Period Ended: May 31, 2000

[ ] Transition Report on Form 10-K           [ ] Transition Report on Form 10-Q
[ ] Transition Report on Form 20-F           [ ] Transition Report on Form N-SAR
[ ] Transition Report on Form 11-K
For the Transition Period Ended:
                                ----------------------

         Nothing in this form shall be construed to imply that the Commission
has verified any information contained herein.

         If the notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification relates:
                                                       -----------------------
                         Part I. Registrant Information

            Full Name of Registrant: Cancer Treatment Holdings, Inc.
                         Former Name if Applicable: N/A
     c/o Carol O'Donnell, Esq., 540 Joan Drive, Fairfield, CT  06430-2207
           Address of principal executive office (Street and Number),
                            City, State and Zip Code

                        Part II. Rule 12b-25 (b) and (c)

         If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check box if appropriate.)

     :  (a) The reasons described in reasonable detail in Part III of this form
     :  could not be eliminated without unreasonable effort or expense;
     :
[X]  :  (b) The subject annual report, semi-annual report, transition report on
     :  Form 10-K, 20-F, 11-K or Form N-SAR, or portion thereof will be filed
     :  on or before the 15th calendar day following the prescribed due date;
     :  or the subject quarterly report or transition report on Form 10-Q, or
     :  portion thereof will be filed on or before the fifth calendar day
     :  following the prescribed due date; and
     :
     :  (c) The accountant's statement or other exhibit required by Rule
     :  12b-25(c) has been attached if applicable.


                               Part III. Narrative

         State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F,
10-Q, N-SAR or the transition report portion thereof could not be filed within
the prescribed time period. (Attach extra sheets if needed.)


                                Page 1 of 2 Pages
<PAGE>

         An extension of time in filing Form 10-KSB is required. The sole
principal of the registrant's accounting firm DFSH, CPA P.C. was severely
injured in a recent car accident. The New York accounting firm of Radin, Glass &
Co., LLP has been engaged by the registrant. The decision to change accountants
was solely based on the incapacity of the sole principal of DFSH, CPA P.C., and
was unanimously approved by the Board of Directors. There were no disagreements
with the former accountant on any matter of accounting principles or practices,
financial statement disclosure, or auditing scope or procedure. The registrant
expects its Form 10-KSB to be filed within 15 calendar days after the prescribed
due date.

                           Part IV. Other Information

(1) Name and telephone number of person to contact in regard to this
    notification:
         Carol O'Donnell                          (203) 254-7765
         Name                                     Area Code and Telephone Number

(2) Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of
1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If the answer is no,
identify report(s).

                                                                 [X] Yes  [ ] No

(3) Is it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof?

                                                                 [ ] Yes  [X] No

         If so: attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the reasons why a
reasonable estimate of the results cannot be made.

                         Cancer Treatment Holdings, Inc.
                  (Name of registrant as specified in charter)

         Has caused this notification to be signed on its behalf by the
undersigned thereunto duly authorized.

Date:  August 28, 2000                                 By:   /s/ Carol O'Donnell
                                                            --------------------
                                                                 Carol O'Donnell
                                                                 Secretary

Instruction. The form may be signed by an executive officer of the registrant or
by any other duly authorized representative. The name and title of the person
signing the form shall be typed or printed beneath the signature. If the
statement is signed on behalf of the registrant by an authorized representative
(other than an executive officer), evidence of the representative's authority to
sign on behalf of the registrant shall be filed with the form.

                                    ATTENTION

         Intentional misstatements or omissions of fact constitute Federal
criminal violations (see 18 U.S.C. 1001).


                                       -2-



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission